Danish-German cardiogenic shock trial-DanGer shock: Trial design update
Jacob Eifer Møller, Oke Gerke, DanGer Shock Investigators, Jacob Eifer Møller, Oke Gerke, DanGer Shock Investigators
Abstract
Background: The main objective of the Danish German Cardiogenic Shock trial (DanGer Shock ClinicalTrials.gov Identifier: NCT01633502) is to assess the efficacy of the trans valvular axial flow device Impella CP in treating patients with AMICS shock due to STEMI undergoing emergency percutaneous coronary intervention.
Methods: This statistical analysis plan represents an overview of the statistical methods which will be used for analyzing the DanGer Shock trial.
Results: The primary study endpoint is death from all causes through 180 days in the intention to treat population (all randomized consented patients). The secondary endpoints comprise; composite event of the need for additional mechanical support, need for cardiac transplantation, and death of all causes whichever comes first; and days alive and out of hospital. As exploratory analyses an as treated analysis of primary endpoint will be performed. Composite safety endpoint will comprise of major bleeding, vascular complications, device malfunction, damage to the aortic valve, and significant hemolysis. The primary endpoint death rate at 180 days will be analyzed using Cox proportional hazards analysis. The result will be reported as hazard ratio and corresponding 95% confidence interval (95% CI). No imputation of missing values will be performed. Additional statistical analyses for predefined hemodynamic, metabolic, renal, hematological, and health economics substudies will be specified in separate protocols.
Conclusion: Main analyses of the primary and secondary outcomes of the DanGer Shock trial will be conducted according to this publication.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed